STOCK TITAN

Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Ironwood Pharmaceuticals (Nasdaq: IRWD) has scheduled its third quarter 2024 investor update conference call and webcast for Thursday, November 7, 2024, at 8:30 a.m. Eastern Time. Investors can join via phone using conference ID 2530602 or through the company's website. A replay will be available until November 21, 2024, and the webcast recording will be accessible on the company's website for one year after the call.

Ironwood Pharmaceuticals (Nasdaq: IRWD) ha programmato la sua conferenza di aggiornamento per investitori del terzo trimestre 2024 per giovedì 7 novembre 2024, alle 8:30 ora orientale. Gli investitori possono partecipare telefonicamente utilizzando l'ID conferenza 2530602 o tramite il sito web dell'azienda. Una registrazione sarà disponibile fino al 21 novembre 2024 e la registrazione della webcast sarà accessibile sul sito web dell'azienda per un anno dopo la conferenza.

Ironwood Pharmaceuticals (Nasdaq: IRWD) ha programado su conferencia de actualización para inversores del tercer trimestre de 2024 para el jueves 7 de noviembre de 2024 a las 8:30 a.m. hora del este. Los inversores pueden unirse por teléfono utilizando el ID de conferencia 2530602 o a través del sitio web de la empresa. Una grabación estará disponible hasta el 21 de noviembre de 2024, y la grabación de la webcast estará accesible en el sitio web de la empresa durante un año después de la llamada.

Ironwood Pharmaceuticals (Nasdaq: IRWD)는 2024년 3분기 투자자 업데이트 컨퍼런스 콜 및 웹캐스트를 2024년 11월 7일 목요일 동부 표준시 기준 오전 8시 30분으로 예정하였습니다. 투자자들은 전화에서 회의 ID 2530602를 사용하거나 회사 웹사이트를 통해 참여할 수 있습니다. 녹화된 영상은 2024년 11월 21일까지 제공되며, 웹캐스트 녹음은 통화 후 1년 동안 회사 웹사이트에서 접근 가능합니다.

Ironwood Pharmaceuticals (Nasdaq: IRWD) a programmé sa conférence de mise à jour pour investisseurs du troisième trimestre 2024 pour le jeudi 7 novembre 2024 à 8h30 heure de l'est. Les investisseurs peuvent rejoindre par téléphone avec l'ID de conférence 2530602 ou via le site web de l'entreprise. Un enregistrement sera disponible jusqu'au 21 novembre 2024, et l'enregistrement de la webdiffusion sera accessible sur le site web de l'entreprise pendant un an après la conférence.

Ironwood Pharmaceuticals (Nasdaq: IRWD) hat sein Update-Conference-Call für Investoren für das dritte Quartal 2024 auf Donnerstag, den 7. November 2024, um 8:30 Uhr Eastern Time angesetzt. Investoren können per Telefon mit der Konferenz-ID 2530602 teilnehmen oder über die Webseite des Unternehmens. Eine Aufnahme wird bis zum 21. November 2024 verfügbar sein, und die Webcast-Aufzeichnung wird ein Jahr nach dem Call auf der Webseite des Unternehmens zugänglich sein.

Positive
  • None.
Negative
  • None.

BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 7, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com.

The call will be available for replay via telephone starting Thursday, November 7, 2024 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, November 21, 2024. To listen to the replay, dial (800) 770-2030 (U.S. and Canada) or (609) 800-9909 (international) using conference ID number 2530602. The archived webcast will be available on Ironwood’s website for 1 year beginning approximately one hour after the call has completed.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years-old. Ironwood is also advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF), as well as several earlier stage assets. Building upon our history of GI innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland.

We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on Twitter and on LinkedIn.

Investors:

Greg Martini, 617-374-5230

gmartini@ironwoodpharma.com

Matt Roache, 617-621-8395

mroache@ironwoodpharma.com

Media:

Beth Calitri, 978-417-2031

bcalitri@ironwoodpharma.com

Source: Ironwood Pharmaceuticals, Inc.

FAQ

When is Ironwood Pharmaceuticals (IRWD) Q3 2024 earnings call?

Ironwood Pharmaceuticals will host its Q3 2024 investor update call on Thursday, November 7, 2024, at 8:30 a.m. Eastern Time.

How can I access IRWD's Q3 2024 earnings call replay?

The replay will be available from November 7, 2024, at 11:30 a.m. ET until November 21, 2024, at 11:59 p.m. ET by dialing (800) 770-2030 (U.S./Canada) or (609) 800-9909 (international) with ID 2530602.

How long will IRWD's Q3 2024 earnings webcast be available?

The webcast recording will be available on Ironwood's website for one year after the call.

Ironwood Pharmaceuticals, Inc. -

NASDAQ:IRWD

IRWD Rankings

IRWD Latest News

IRWD Stock Data

713.72M
158.96M
1.69%
110.22%
7.47%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
BOSTON